Environmental, social, and governance issues are gaining greater attention among investors, but only 30% of development-stage, publicly traded biotech companies reference these topics in their regulatory filings and other disclosures, a new survey found.
Even so, 76% of biotech executives agreed that so-called ESG disclosures should be mandated. But among those who maintained disclosures should not be required, two-thirds argued that the metrics are unclear and one-third also acknowledged they lack the internal resources to track any metrics, according to the survey conducted by the Fenwick & West law firm.
Create a display name to comment
This name will appear with your comment